GLAXOSMITHKLINE vs Sanofi-Aventis Deutschland GmbH: FDA Enforcement Comparison

GLAXOSMITHKLINE and Sanofi-Aventis Deutschland GmbH have an identical total of 1 FDA records tracked by Argus HQ.

GLAXOSMITHKLINE: 0 warning letters, 0 recalls, 1 approval record, 0 Form 483s.

Sanofi-Aventis Deutschland GmbH: 0 warning letters, 0 recalls, 0 approval records, 1 Form 483.

Side by side

GLAXOSMITHKLINE — Warning letters0

Sanofi-Aventis Deutschland GmbH — Warning letters0

GLAXOSMITHKLINE — Recalls0

Sanofi-Aventis Deutschland GmbH — Recalls0

GLAXOSMITHKLINE — Approval records1

Sanofi-Aventis Deutschland GmbH — Approval records0

GLAXOSMITHKLINE — Form 483s0

Sanofi-Aventis Deutschland GmbH — Form 483s1

Timeline

GLAXOSMITHKLINE

Most recent FDA action: June 17, 2026

Full history →

Sanofi-Aventis Deutschland GmbH

Most recent FDA action: January 16, 2025

Full history →

Cite this comparison

Pre-formatted for a story, footnote, or reference list:

"GLAXOSMITHKLINE vs Sanofi-Aventis Deutschland GmbH: FDA Enforcement Comparison." Argus HQ, accessed July 15, 2026. https://argushq.ai/compare/glaxosmithkline-vs-sanofi-aventis-deutschland-gmbh

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗